Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Monopar Therapeutics Inc.NASDAQ: MNPR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $3.89M (cash outflow) rose 48.3% year over year, ahead of the -9.6% change in trailing-twelve-month net income. Sequentially, it fell 25.1% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$20.16M (+47.0%) for the fiscal year ending Dec 2026, a step up from the -12.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.89M-25.1% QoQ
- Last fiscal yearDec 2025
- -$13.72M-12.0% YoY
- LTMMar 2026
- -$14.98M-9.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +48.3% | +108.9% | +60.6 pp |
| 1 year | -12.0% | +47.0% | +59.0 pp |
| 3-year CAGR | +9.3% | +13.1% | +3.9 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (13.72M) USD
- Year-over-year change
- +12.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (13.72M) | +12.0% |
| FY2024 | 2024-12-31 | (15.59M) | -85.5% |
| FY2023 | 2023-12-31 | (8.4M) | +20.1% |
| FY2022 | 2022-12-31 | (10.52M) | -15.5% |
| FY2021 | 2021-12-31 | (9.1M) | — |
Net Income vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -9.6% is the 9th highest of 11, against a peer median of +15.3%.
- Over three fiscal years its annual growth of +9.3% compares with a peer median of +0.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $282.65M USD | +26.9% | +79.2% | — | |
| LTM Mar 2026 | $218.8M USD | +7.2% | +24.8% | 344.6% | |
| LTM Mar 2026 | $136.99M USD | -8.6% | -3.2% | 173.0% | |
| LTM Mar 2026 | $88.87M USD | -31.7% | -6.3% | — | |
| LTM Jun 2026 | $71.19M USD | -60.8% | +18.5% | 67.8% | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $68.17M USD | +23.5% | +19.2% | — | |
| FY2025 | €49.18M EUR | -0.6% | -5.4% | 1764.5% | |
| LTM Sep 2026 | $43.31M USD | +168.3% | — | 16.3% | |
| LTM Mar 2026 | $14.98M USD | -9.6% | +9.3% | — | |
| LTM Jun 2026 | $11.31M USD | +127.6% | +0.9% | 32.2% | |
| Peer median (excluding MNPR) | — | +15.3% | +0.9% | 67.8% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.47M | 1.64M | 1.9M | 1.14M | 4.84M |
| Change in Working Capital | 317.77K | 1.65M | (1.35M) | 3.49M | (2.61M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 403.97K | 1.48M | (1.33M) | 506.79K | 388.22K |
| Other Working Capital | (86.2K) | 167.52K | (20.41K) | 2.98M | (2.99M) |
| Other Non-Cash Items | 0 | 0 | 0 | 4.55M | (716.46K) |
| Operating Cash Flow | (7.32M) | (7.23M) | (7.86M) | (6.4M) | (12.2M) |
| Capital Expenditures | 1 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (4.92M) | (7.88M) | (15.32M) | (87.15M) |
| Sales of Investments | 0 | 0 | 12.81M | 985.73K | 23.7M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (4.92M) | 4.93M | (14.34M) | (63.45M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 10.93M | 109.34K | 2.07M | 59.4M | 127.71M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (35M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (45.78K) | (76.46K) | (46.97K) | (104.14K) | (1.13M) |
| Financing Cash Flow | 10.88M | 32.87K | 2.03M | 59.29M | 91.57M |
| Effect of Forex Changes | 4.62K | (3.48K) | (16.8K) | 494 | 97.27K |
| Net Change in Cash | 3.57M | (12.12M) | (920.11K) | 38.55M | 16.02M |
| Free Cash Flow | (7.32M) | (7.23M) | (7.86M) | (6.4M) | (12.2M) |
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.